1971) Philips Electron Optics Micrion (Acq 1999) MTI-GlobalStem (Acq 2016) Finesse Solutions, Inc. (Acq 2017) Core Informatics (Acq 2017) Patheon (Acq 2017) Agere Pharmaceuticals (Acq 2015) Gallus Pharmaceuticals (Acq 2014) Royal DSM NV (Pharmaceutical div, merged 2014) MOVA (Acq 2004) Banner Pharmacaps (Acq 2013) Brammer Bio (Acq 2019) Phitonex, Inc. (Acq 2020) Henogen S.A. (Acq 2021) Mesa Biotech, Inc. (Acq 2021) PPD, Inc. (Acq 2021) Acurian (Acq 2013) Evidera (Acq 2016) Medimix (Acq 2019) PharmaFluidics (Acq 2021) PeproTech (Acq 2021) The Binding Site Group (Acq 2023) Research partnership In September 2017, Thermo Fisher Scientific signed an agreement with the Institute of Pathology Heidelberg (IPH) to establish its Center of Molecular Pathology at Heidelberg University Hospital as the newest member of the Next Generation Sequencing Companion Dx Center of Excellence Program (COEP). The initiative focuses on establishing strategic collaborations with leading, European-based organizations that can lead studies using Thermo Fisher's Oncomine portfolio of research panels destined for development as companion diagnostics to help drive precision oncology in the region. Controversies Xinjiang In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang. In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program. A report from the Australian Strategic Policy Institute found that Thermo Fisher Scientific collaborated with the Chinese Ministry of Public Security to develop a Huaxia PCR amplification kit specifically to identify the genotypes of Uyghur, Tibetan and Hui ethnic minorities. In June 2021, The New York Times reported that, despite bans, Thermo Fisher Scientific equipment continued to be sold to police in Xinjiang. HeLa cells In October 2021 the estate of Henrietta Lacks sued to get past and future payment for the alleged and widely known unauthorized sale by Thermo Fisher Scientific of her HeLa cells which are essential in many types of research. Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more. In May of 2022, it was announced Thermo Fisher Scientific went to court to seek a dismissal of the lawsuit. Mexican plant In 2013, Opengate Capital Group LLC filed suit against Thermo Fisher Scientific for selling it a manufacturing plant controlled by a drug